Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI

Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.

September 9, 2015 7:57 AM EDT

Guggenheim reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ: TTPH), and cut the price target to $20.00 (from $60.00), on disappointing cUTI data.

Analyst Louise Chen commented, "Despite disappointing cUTI data, we are maintaining our BUY rating for TTPH shares, but we are lowering our price target from $60 to $20. The decrease in our PT is driven by downwards earnings revisions and multiple contraction. In... More